BGBIOO Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BerGenBio ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 11.88 |
| 52 Week High | NOK 30.28 |
| 52 Week Low | NOK 20.90 |
| Beta | 1.61 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.50% |
| 5 Year Change | n/a |
| Change since IPO | -99.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| BGBIOO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 2.2% |
| 1Y | n/a | -17.9% | 8.8% |
Return vs Industry: Insufficient data to determine how BGBIOO performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how BGBIOO performed against the UK Market.
Price Volatility
| BGBIOO volatility | |
|---|---|
| BGBIOO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BGBIOO has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BGBIOO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 15 | Martin Olin | www.bergenbio.com |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors.
BerGenBio ASA Fundamentals Summary
| BGBIOO fundamental statistics | |
|---|---|
| Market cap | NOK 371.56m |
| Earnings (TTM) | -NOK 155.40m |
| Revenue (TTM) | NOK 521.00k |
713.2x
P/S Ratio-2.4x
P/E RatioIs BGBIOO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGBIOO income statement (TTM) | |
|---|---|
| Revenue | NOK 521.00k |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 521.00k |
| Other Expenses | NOK 155.93m |
| Earnings | -NOK 155.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 13, 2024
| Earnings per share (EPS) | -3.98 |
| Gross Margin | 100.00% |
| Net Profit Margin | -29,828.22% |
| Debt/Equity Ratio | 0% |
How did BGBIOO perform over the long term?
See historical performance and comparison